Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.

Key facts

Study ID

NCT00478205

Run by

Eisai Inc.

People needed

1467

Starts

2007-06-01

Last updated by the study team

2014-07-11

Who can join

Age: 45 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

Where it is running

• MedTrials, Inc. — Hickory, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.